Latest Ratios: P/E Ratio -13.8x · EV/EBITDA N/A · ROE -895.3%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $291M | $284M | $146M | $135M | $196M | $315M | $463M | — | — | — |
| Enterprise Value | $297M | $291M | $142M | $128M | $183M | $288M | $435M | — | — | — |
| P/E Ratio → | -13.85 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 149.69 | 158.83 | 57.68 | 20.17 | 14.85 | 11.74 | 16.77 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -895.3% | -895.3% | -377.2% | -89.3% | -39.1% | -16.8% | -14.2% | — | — | — |
| ROA | — | — | -314.1% | -86.9% | -38.5% | -16.4% | -13.0% | -5066.4% | -2491.2% | -5805.3% |
| ROIC | -418.5% | -418.5% | — | — | — | — | — | — | — | — |
| ROCE | — | — | -382.0% | -93.7% | -40.2% | -16.9% | -14.2% | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 0.01 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 3.76 | -1.61 | -1.04 | -1.02 | -1.01 | -1.03 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | — | — | 2.62 | 23.74 | 51.23 | 70.63 | 27.41 | 0.00 | 0.12 | 0.00 |
| Quick Ratio | — | — | 2.62 | 23.74 | 51.23 | 70.63 | 27.41 | 0.00 | 0.12 | 0.00 |
| Cash Ratio | — | — | 2.62 | 23.74 | 51.23 | 70.63 | 27.41 | 0.00 | 0.12 | 0.00 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 3.8% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 3.8% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $14M | $13M | $13M | $13M | $13M | $13M | $12M | $12M | $12M |
Critical Liquidity and Dilution
According to recent market data, GLSI trades at a price-to-book ratio of 149.69, a figure that reflects extreme investor optimism regarding the FLAMINGO-01 trial outcomes rather than any tangible asset base, as the company remains entirely pre-revenue and dependent on future equity-based capital infusions.
The elevated P/B multiple suggests that the market is pricing in a high probability of success for the GP2 peptide, effectively ignoring the current lack of commercial viability. Investors should monitor whether this valuation premium can be sustained as the company approaches potential dilutive financing events required to address its negative cash position.
Based on reported financial statements, the company's ROIC has plummeted to -2.6% in 2026Q1, illustrating a persistent decay in capital efficiency as the firm consumes its remaining resources to fund late-stage clinical development without generating any offsetting returns on invested capital.
The negative return profile is a direct consequence of the high fixed-cost structure inherent in clinical-stage biotechnology. This trend suggests that the company is currently destroying shareholder value in the short term, with any potential for compounding returns entirely contingent on the successful commercialization of its single therapeutic candidate.
As reported in recent filings, the company's liquidity position has deteriorated into a negative cash balance of $6.7 million, a critical indicator that suggests the firm may face significant challenges in meeting its immediate obligations without urgent and potentially dilutive external financing.
The current ratio of 2.01, while appearing superficially healthy, is undermined by the underlying negative cash position and the lack of revenue generation. This suggests that the company's ability to maintain its clinical trial momentum is highly sensitive to market conditions and the availability of capital markets for further equity issuance.
Analysts frequently misapply the price-to-earnings ratio to GLSI, which is fundamentally flawed given the company's pre-revenue status and the fact that its TTM P/E of -13.85 obscures the true economic reality of its R&D-driven cash burn and long-term clinical development risks.
Using P/E or EV/EBITDA for a clinical-stage firm like Greenwich LifeSciences ignores the binary nature of its business model, where value is derived from clinical trial milestones rather than operational earnings. Investors should instead focus on the 'Cash Runway Ratio' and the 'Net Cash Burn' per quarter to better assess the company's survival probability and the likelihood of future shareholder dilution.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GLSI stock.
Greenwich LifeSciences, Inc.'s current P/E ratio is -13.8x. This places it at the 50th percentile of its historical range.
Greenwich LifeSciences, Inc.'s return on equity (ROE) is -895.3%. The historical average is -107.3%.
Based on historical data, Greenwich LifeSciences, Inc. is trading at a P/E of -13.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.